A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination with Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

开始日期2025-12-31

申办/合作机构

University of Maryland Baltimore

[+1]

NCT06769126

/ Not yet recruiting临床2期IIT

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

开始日期2025-09-08

申办/合作机构

SWOG

[+1]

NCT06719973

/ Not yet recruiting临床1期

An Open Label, Multicenter, Phase 1 Study of the PARP1 Inhibitor M9466 in Combination With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary clinical activity of M9466 in combinations with carboplatin in advanced or metastatic refractory solid tumor and with the standard of care (carboplatin, etoposide, and atezolizumab) in treatment-naïve ES-SCLC. The results will support any investigation of carboplatin-based combination anticancer treatments with M9466 as well as the selection of a RP2D of M9466 in combination with carboplatin, etoposide, and atezolizumab for a subsequent ES-SCLC study.

开始日期2025-07-01

申办/合作机构

EMD Serono Research & Development Institute, Inc.

[+1]

100 项与依托泊苷相关的临床结果

登录后查看更多信息

100 项与依托泊苷相关的转化医学

登录后查看更多信息

100 项与依托泊苷相关的专利（医药）

登录后查看更多信息

34,722

项与依托泊苷相关的文献（医药）

2025-12-31·NMC case report journal

A Primary Spinal Intramedullary Mixed Germ Cell Tumor: A Case Report and Literature Review

Article

作者: SHIMAUCHI-OHTAKI, Hiroya ; HORIGUCHI, Keishi ; HIRATO, Junko ; NAKATA, Satoshi ; HONDA, Fumiaki ; YOKOO, Hideaki ; OYA, Soichi ; GOTO, Yuta ; TOMOMASA, Ran ; NAKAMURA, Shunsuke

Central nervous system germ cell tumors are rare and account for 2% to 3% of all central nervous system tumors in Japan. Here, we report an extremely rare case of a primary spinal intramedullary mixed germ cell tumor. A 33-year-old man presented with a chief report of dysuria and numbness in the right lower extremity. Magnetic resonance imaging revealed a mass lesion on the left side of the intramedullary spinal cord at the Th10-11 vertebral body level with hyperintensity on T2-weighted images, isointensity on T1-weighted images, and uniform contrast in gadolinium. Cerebrospinal fluid examination revealed a few atypical cells. Although tumor removal using the posterior median sulcus approach was attempted, only a biopsy was performed because intraoperative rapid pathology suggested a possible diagnosis of germinoma. Permanent pathology revealed a mixed germ cell tumor (mainly comprising a germinoma with a yolk sac tumor). Postoperatively, cerebrospinal irradiation and 8 courses of the carboplatin and etoposide regimen were administered. No recurrence or new lesions were observed on magnetic resonance imaging at 94 months postoperatively. Our extensive literature search found only 4 cases of a mixed germ cell tumor of primary intramedullary origin in the spinal cord. Most spinal germ cell tumors described in the literature are either germinomas or mature teratomas; however, mixed germ cell tumors can also occur, albeit infrequently. Although additional cases need to be accumulated, our case suggests that yolk sac elements in spinal mixed germ cell tumors might not be directly associated with poor life expectancy.

2025-06-01·TRANSFUSION AND APHERESIS SCIENCE

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma

Article

作者: Du, Xiaohong ; Zhuang, Xianxu ; Ye, Peipei ; Cheng, Yixuan ; Xu, Sishi ; Li, Shuangyue ; Fang, Ying ; Wu, Mengjie ; Zhuang, Haihui ; Lu, Ying ; Pei, Renzhi ; Chen, Dong

BACKGROUND:

In multiple myeloma (MM) or lymphoma with poor mobilization, the combination of etoposide, cytarabine (Ara-C), and pegfilgrastim (EAP) appears to have higher mobilization efficacy than cyclophosphamide (Cy) plus granulocyte colony-stimulating factor (G-CSF) (CG) regimens. The purpose of this study was to examine whether there were differences in efficacy and toxicity between the two mobilization regimens.

METHODS:

All data were collected from Department of Hematology at the Affiliated People's Hospital of Ningbo University from May 2016 to March 2023. And data from EAP regimen were compared with data from the CG regimen.

RESULTS:

A total of 43 patients were mobilized by the EAP regimen and 44 patients by the CG regimen. The target yield of 2 × 10⁶ CD34⁺ cells/kg was achieved in 95.3 % (EAP) and 63.6 % (CG) of patients by 1.3 and 1.6 apheresis (means), respectively. In addition, 76.7 % of patients with EAP regimen and 29.5 % of patients with CG regimen achieved optimal mobilization (≥5 ×10⁶ CD34⁺ cells/kg) during the first apheresis session. The median number of cumulative collected CD34⁺ cells was 8.9 (range 2.6-41.3) × 10⁶ CD34⁺ cells/kg and 4.2 (range 0.1-18.8) × 10⁶ CD34⁺ cells/kg in the two groups, respectively. Thrombocytopenia gr. 4 was observed in 34.9 % of patients after EAP (CG, 2.3 %) and neutropenia gr. 4 was observed in 58.1 % of patients after EAP (CG, 63.6 %).

DISCUSSION:

EAP is an excellent mobilization regimen with acceptable toxicity and could be considered in patients with MM and lymphoma with poor mobilization.

2025-05-01·Radiology case reports

Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab

Article

作者: Golemba, Alfredo S ; Santamaría, Astor A Aguirre ; Tolosa, Raúl E García

Two basic criteria must be met for the diagnosis of extrapulmonary small cell carcinoma (EPSCC): the tumor must present histological characteristics of small cell carcinoma and a primary small cell lung carcinoma must be ruled out. We present the case of a 52-year-old woman who presented 8 months prior to consultation with an increase in abdominal circumference, epigastric pain and early satiety. Abdominal MRI showed an enlarged liver secondary to a mass affecting segments IV, V, VI, VII and VIII of 16.9 × 9.4 cm. Biopsy of the liver lesion was performed: small, round, blue cell neoplasm; immunohistochemistry revealed positivity for CKA1/A3, chromogranin, synaptophysin, CD56 and TTF-1. The diagnosis of EPSCC of the liver was made. It was decided to start systemic chemotherapy treatment with carboplatin, etoposide and durvalumab with clinical improvement of the symptoms. The patient died 10 months after starting chemoimmunotherapy treatment. Optimal treatment of EPSCC is generally extrapolated from small lung cell cancer. There is insufficient evidence to routinely recommend the use of immunotherapy in this group of patients.

674

项与依托泊苷相关的新闻（医药）

2025-04-03

·必贝特医药

BEBT-908治疗复发/难治性弥漫性大B细胞淋巴瘤III期临床研究招募广告

由广州必贝特医药股份有限公司申办，经国家药品监督管理局批准(通知书编号：2024LP00110)的“BEBT-908联合利妥昔单抗（R）对比利妥昔单抗-吉西他滨-奥沙利铂（R-GemOx）或利妥昔单抗-异环磷酰胺-卡铂-依托泊苷（R-ICE）治疗复发/难治性弥漫性大B细胞淋巴瘤（r/rDLBCL）有效性和安全性的多中心、随机、对照、开放性III期临床研究”正在全国60家中心进行，预计入组416例左右受试者，该研究已经得到研究中心伦理委员会批准。 BEBT-908是全新化学结构磷脂酰肌醇3激酶(PI3Ka)抑制剂/组蛋白去乙酰化酶(HDAC)双靶点抑制剂。与先前的靶向药物不同，这种双靶点药物通过选择性抑制具有协同作用肿瘤细胞信使核心蛋白激酶靶点和表观遗传靶点HDAC，破坏肿瘤细胞信使网络，从而杀灭肿瘤细胞。BEBT-908在各种淋巴瘤、多发性骨髓瘤、淋巴细胞白血病的肿瘤模型均显示其能导致肿瘤生长停滞和消退。入选条件1.年龄在18-75周岁之间。2.中心病理确诊为弥漫大B细胞淋巴瘤。3.须至少经过1种系统治疗后复发或难治性弥漫大B细胞淋巴瘤，并且至少有1种系统治疗中包含CD20抗体。如果您想了解本研究更多信息，请致电：杨老师，电话：13318748717。医生将在判断您的病情后，决定您是否适合参加本研究。本研究的参加中心如下关于BEBT-908BEBT-908是全球首个HDAC/PI3Ka双靶点抑制剂，由广州必贝特医药股份有限公司核心团队成员发明，并由公司自主完成开发工作。目前，本品已完成单药治疗复发/难治性弥漫性大B细胞淋巴瘤(r/rDLBCL)的关键单臂II期临床试验，其新药上市申请(NDA)已于2023年10月获得受理，先后被纳入突破性治疗品种和优先审评程序。关于必贝特广州必贝特医药股份有限公司于2012年创立，公司秉承“矢志创新，追求更好”的愿景，以临床价值为导向、专注于创新药研究、开发与商业化的生物医药企业。公司专注肿瘤、自身免疫性疾病、代谢性疾病等重大疾病领域，持续开发临床急需的全球首创药物（First-in-Class）和针对未满足临床需求的创新药物，现已建立多领域、多类型、全球布局的研发管线。

临床2期临床3期优先审批申请上市

2025-04-02

·微信

EBMT中国之声丨李智慧教授：从预处理方案优化到改善NKTCL患者生存的全面布局

EBMT 2025NK/T细胞淋巴瘤（NKTCL）是一种高度侵袭性的非霍奇金淋巴瘤亚型，主要起源于自然杀伤（NK）细胞或NK样T细胞，与EB病毒（EBV）感染密切相关，预后较差。2025年3月30日至4月2日，第51届欧洲血液与骨髓移植学会年会（EBMT 2025）在“文艺复兴的摇篮”意大利佛罗伦萨盛大举行。在本届大会上，北京高博博仁医院李智慧教授的一项研究（P203）入选壁报展示，探讨了含替尼泊苷预处理方案的异基因造血干细胞移植（allo-HSCT）治疗NK/T细胞淋巴瘤的疗效和安全性。《肿瘤瞭望-血液时讯》现场特邀李智慧教授深入解读该研究，并分享团队对改善NKTCL患者生存的全面布局。《肿瘤瞭望-血液时讯》您团队选择替尼泊苷（VM26）作为allo-HSCT治疗NK/T细胞淋巴瘤预处理方案的核心药物，是基于哪些考虑？李智慧教授替尼泊苷为半合成鬼臼毒素衍生物，其脂溶性较高，理论上更易穿透血脑屏障（BBB）及组织屏障。研究表明，替尼泊苷在中枢神经系统（CNS）淋巴瘤中的浓度可达血浆浓度的10%～20%，显著优于依托泊苷（VP-16）等同类药物[1]。本研究中，VM26组CNS受累患者在接受治疗后脑脊液EBV-DNA及流式迅速转阴（平均14天），而非VM26组需依赖移植后免疫重建才转阴，提示替尼泊苷可能通过直接渗透至CNS发挥早期抗肿瘤作用。这与既往文献中替尼泊苷用于原发性CNS淋巴瘤的疗效报道一致[2]。《肿瘤瞭望-血液时讯》您提到VM26组PET-CT缓解率更高（82.4% vs. 50%），但两组总生存率无显著差异。这是否提示VM26可能更适用于特定亚组患者（如结外多部位受累者）？未来是否会针对患者分层优化预处理方案？李智慧教授VM26组PET-CT缓解率高，但是两组生存没有显著性差异，这可能与患者数量少和生存期观察时间较短有关系。结外NK/T细胞淋巴瘤（ENK/TCL）常累及鼻腔、皮肤、软组织等富含间质的部位，替尼泊苷的高组织渗透性可能增强对这些“庇护所”病灶的清除能力。本研究中VM26组PET-CT缓解率更高（82.4% vs. 50%），可能与其对多部位病灶的覆盖能力相关。ENK/TCL对传统化疗方案（如CHOP）耐药率高，而含替尼泊苷的方案（如SMILE等）已被证实可提高缓解率[3]，因此未来会考虑针对患者情况做分层优化处理。《肿瘤瞭望-血液时讯》作为深耕移植技术与血液肿瘤创新的团队，去年ASH就大会口头发言报道了异基因移植治疗NK/T细胞淋巴瘤的生存结果，今年又报道了替尼泊苷治疗NK/T淋巴瘤的安全性和有效性，请问未来是否会聚焦NK/T细胞淋巴瘤的异基因移植，以及有何治疗想法？李智慧教授与B细胞淋巴瘤不同，尽管现代靶向药物和免疫治疗手段不断涌现，但外周T细胞淋巴瘤（PTCL）的治疗至今尚未取得重大突破（NKT细胞淋巴瘤就是PTCL中的一种特殊类型）。因此，自体与异基因造血细胞移植（HCT）仍是PTCL治疗的核心策略。对化疗敏感且符合移植条件的患者常采用自体HCT（auto-HCT）进行巩固强化，复发/难治性（R/R）患者则应实施异基因HCT（allo-HCT）。现代异基因移植平台的改良预处理方案的进展等显著降低了移植相关并发症及死亡率，使高龄及合并症患者亦可接受allo-HSCT，但移植后复发仍是主要挑战。降低复发风险的策略需聚焦于更有效的移植前减瘤，包括可能用于移植后维持的新型药物，及在疾病过度耐药或患者状态恶化前尽早实施allo-HSCT。真实世界研究中较低的移植比例提示R/R PTCL患者中HCT应用严重不足。基于遗传学不良特征及分子/代谢反应标志物的风险分层策略可能推动一线allo-HSCT在NKT细胞淋巴瘤中的重新评估。本届EBMT大会上，来自德国明斯特大学医院的Philipp Berning教授等报告了一项重要的研究成果（摘要号：OS10-04）——关于异基因造血细胞移植与自体造血干细胞移植在治疗自然杀伤/T细胞淋巴瘤（NKTCL）中的比较分析，是基于研究者既往对allo-HSCT受者的大型EBMT队列的分析（Berning等，Leukemia 2023）。该研究比较了auto-HCT和allo-HSCT在相关临床情况下的治疗结局。结果显示，虽然在CR/PR 1患者中，allo-HSCT和auto-HCT之间的主要治疗结局没有观察到显著差异，但在复发/难治性背景下，allo-HSCT的复发率（RI）较低，患者是可以取得生存获益的，这与我们去年在ASH大会口头发言的研究结论基本一致。我们的研究发现NKT细胞淋巴瘤患者，如果移植前有慢性活动性EBV感染（CAEBV）病史、疾病NR状态、移植后EBV再激活均会对患者生存产生负面影响。因此针对这些情况，我们将与首都医科大学附属北京友谊医院王昭教授合作，加强对于EBV的管理和清除，以及与雅科公司张鸿声教授联合开展免疫细胞治疗研究，通过CAR-T治疗同时达到清除EB病毒和消灭NKT肿瘤细胞的双重作用，这也是当前NKT细胞淋巴瘤治疗过程中的痛点和难点。未来我们对于进一步提高复发难治性晚期NKTCL患者的生存充满信心。研究简介背景本研究旨在评估含替尼泊苷（VM26）预处理方案的异基因造血干细胞移植（allo-HSCT）在NK/T细胞淋巴瘤（NKTCL）患者中的安全性和有效性。方法2019年1月至2024年11月，共纳入33例NKTCL患者进行分析，其中男性18例（54.5%），女性15例（45.5%），中位年龄30.3岁（范围：6-59岁）。75.7%的患者（n=24）有结外受累，主要受累部位包括：中枢神经系统（CNS）（n=6，25%）、皮肤（n=8，33.3%）、肌肉软组织（n=3，9.1%）、骨骼（n=2，6.1%）、前列腺（n=1，3.0%）、肾上腺（n=1，3.0%）、肺（n=1，3.0%）、睾丸（n=1，3.0%）和眼眶（n=1，3.0%）。在VM26组中，有17例患者，其中12例有结外受累；在非VM26组中，有16例患者，其中12例有结外受累。所有患者均为III期或IV期，其中78.8%为IV期。4例患者（12.1%）在自体移植后复发并接受了第二次异基因HSCT（VM26组2例，非VM26组2例）。移植前疾病状态：完全缓解（CR）（n=11，33.3%）、部分缓解（PR）（n=6，18.2%）、未缓解（NR）（n=16，48.5%）。移植类型为半相合（n=17，51.5%）和无关供者（n=16，48.5%）。所有患者均接受了清髓性预处理方案：BU/Flu（n=26，78.8%）、TBI/Flu（n=5，15.2%）、TBI/Cy（n=2，6.1%）。移植后的中位随访时间为20.4个月（95%CI：18.7～26.3个月）。在VM26组中，所有患者在诱导化疗和预处理方案中均使用了VM26（化疗剂量为100 mg/d×3天，预处理方案剂量为100 mg/m²/d×3天）。结果除年龄外，VM26组和非VM26组在基线时无显著差异。VM26组患者中位年龄为32.01岁（范围：23-59岁），而非VM26组患者中位年龄为26.57岁（范围：6-41岁）。关于中枢神经系统受累情况，在VM26组中，有3例（均为中枢神经系统EB病毒阳性，1例中枢神经系统流式细胞术阳性；在接受含VM26方案化疗后，脑脊液流式细胞术和病毒均转阴，平均转阴时间为14天；移植后，脑脊液EB病毒和流式细胞术水平保持阴性）。在非VM26组中，也有3例（均为中枢神经系统EB病毒阳性，1例中枢神经系统流式细胞术阳性；在接受化疗后，脑脊液未转阴，但移植后脑脊液EB病毒和流式细胞术水平保持阴性）。两组均基本实现完全嵌合。VM26组中性粒细胞和血小板植入时间分别为11天和13天；非VM26组分别为11天和12天。在VM26组中，5例（29.4%）发生急性移植物抗宿主病（aGVHD）；在非VM26组中，4例（25%）发生aGVHD。在VM26组中，有4例（23.5%）发生EB病毒激活和3例（17.6%）发生巨细胞病毒（CMV）激活；在非VM26组中，有4例（25%）发生EB病毒激活和7例（43.7%）发生CMV激活。PET-CT评估移植前后的有效性如下：VM26组（n=14，82.4%），非VM26组（n=8，50%），两组间无显著差异（P=0.07）。然而，在VM26组中，5例患者在接受含VM26方案化疗后PET-CT评估显示显著缓解。此外，两组在总生存率（OS）和复发率方面无显著差异（OS：两组中位OS均未达到，P=0.4；累积复发率，P=0.69；非复发死亡率，P=0.17）。在VM26组中，4例死亡；在非VM26组中，5例死亡。未观察到3级或以上替尼泊苷相关的不良反应；最常见的不良反应为胃肠道反应、脱发和骨髓抑制，停药后均缓解。结论含VM26预处理方案的allo-HSCT在NK/TCL患者中显示出良好的安全性。与非VM26组相比，VM26组在中枢神经系统白血病缓解时间和PET-CT评估的缓解率方面表现出优势。两组在总生存率、复发率、aGVHD和病毒感染方面无显著差异。参考文献：[1]DeAngelis LM, et al. Blood. 1995;85(4):1055-1059.[2]Ferreri AJM, et al. J Clin Oncol. 2009;27(23):3864-3867.[3]Yamaguchi M, et al. J Clin Oncol. 2018;36(1):33-41.专家简介李智慧教授北京高博博仁医院高博医学（血液病）北京研究中心北京高博博仁医院血液二科（造血干细胞移植）病区主任，主任医师，医学博士。专业擅长：长期深耕于血液内科临床工作及实验室研究工作，在CAR-T桥接造血干细胞移植（allo-HSCT）治疗B-ALL系/T-ALL系白血病、NK/T细胞淋巴瘤、噬血细胞综合征、再生障碍性贫血、骨髓增生异常综合征MDS等疾病及移植合并症的防治方面具有非常丰富的经验。学术任职：血液病数字诊疗专业委员会副主任委员；中国医药生物技术协会医药生物技术临床应用专业委员会委员；中国抗癌协会血液肿瘤专业委员会委员；全国肿瘤营养学会儿童肿瘤营养学会委员；中国研究型医院学会感染与炎症放射学专业委员会委员；北京癌症防治学会造血干细胞移植专业委员会委员。Radiology Science国际英文杂志编委（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床研究细胞疗法

2025-04-02

·PMLiVE

BeiGene’s Tevimbra recommended by CHMP to treat small cell lung cancer

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as part of a first-line combination treatment for an aggressive form of lung cancer. The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with etoposide and platinum chemotherapy to treat adults with extensive-stage small cell lung cancer (SCLC). Lung cancer is the leading cause of cancer-related deaths globally and SCLC, which grows and spreads more quickly than other types of the disease, accounts for around 15% of all cases. Approximately 70% of SCLC patients are diagnosed with extensive-stage disease, classed as SCLC that has spread throughout or beyond the lungs, or exceeded an area that can be treated with radiation therapy alone. BeiGene’s Tevimbra is a humanised immunoglobulin G4 anti-PD-1 monoclonal antibody that is designed to help the body’s immune cells detect and fight tumours. The drug is already approved in the EU to treat certain cases of oesophageal squamous cell carcinoma (ESCC), gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and non-small lung cancer. The CHMP’s latest decision was based on positive results from the phase 3 RATIONALE-312 trial, in which the Tevimbra combination was associated with a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus chemotherapy in adults with extensive-stage SCLC. Median OS was 15.5 months for Tevimbra plus chemotherapy compared to 13.5 months for placebo plus chemotherapy, representing a 25% reduction in the risk of death, and BeiGene’s combination was found to be generally well tolerated with no new safety signals identified. Mark Lanasa, chief medical officer, solid tumours at BeiGene, said: “[This] positive CHMP opinion marks another important step for Tevimbra to potentially expand its indications in a fourth disease area in Europe to reach more patients affected by cancer.” The European Commission (EC) will now review the CHMP’s recommendation as it makes a final decision on Tevimbra in extensive-stage SCLC. The positive opinion comes four months after the EC approved Tevimbra for use alongside platinum- and fluoropyrimidine-based chemotherapy to treat patients with HER2-negative locally advanced unresectable or metastatic G/GEJ adenocarcinoma, and in combination with platinum-based chemotherapy for those with unresectable, locally advanced or metastatic ESCC.

临床结果上市批准临床3期免疫疗法放射疗法

100 项与依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00125	依托泊苷	L01CB01	DB00773

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膀胱癌	日本	Clinigen Ltd.	1987-04-30
白血病	日本	Clinigen Ltd.	1987-04-30
淋巴瘤	日本	Nippon Kayaku Co., Ltd.	1987-03-31
卵巢癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
宫颈癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
小细胞肺癌	美国	Corden Pharma Latina SpA	1983-11-10
睾丸肿瘤	美国	Corden Pharma Latina SpA	1983-11-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性卵巢癌	临床3期	中国	江苏恒瑞医药股份有限公司	2019-08-16
原发部位不明恶性肿瘤	临床3期	美国	Pharmacia & Upjohn, Inc.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	AstraZeneca PLC	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	Eli Lilly & Co.	2003-09-01
广泛期小细胞肺癌	临床3期	美国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	中国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	奥地利	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	比利时	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	巴西	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	保加利亚	GSK Plc	2001-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03980925 (GETNE T1913, CTgov)	临床2期	胃肠道神经内分泌肿瘤 \| 胃肠胰神经内分泌肿瘤	37	Nivolumab+Etoposide+Carboplatin	繭網鹽遞構鹽鹽範膚餘 = 艱襯醖夢憲憲構築窪觸鏇繭窪憲遞繭鹹廠艱廠 (鹽願鬱壓夢壓夢蓋襯廠, 網築鹹鏇獵鹽製膚壓顧 ~ 範鬱築廠選糧範鹽襯鬱) 更多	-	2025-03-25
NCT02705508 (Pubmed \| Hematology) 人工标引	临床2期	结外NK-T细胞淋巴瘤一线	34	PEG (pegaspargase, etoposide, gemcitabine)	範壓窪繭繭憲壓襯餘簾(鬱構選獵鹹鏇膚願網齋) = 顧鹹範壓積築壓觸鹽簾網繭觸憲網艱觸膚鬱壓 (鏇窪窪膚夢繭範齋蓋獵 ) 更多	积极	2024-12-31
NCT04923776 (CTgov)	临床2期	广泛期小细胞肺癌	2	Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab	願廠廠顧願襯襯淵淵製(廠鑰膚網糧顧醖壓餘獵) = 簾獵築醖積構構襯願選淵簾簾顧蓋鹹淵醖淵積 (淵壓鏇窪網選淵鏇獵艱, 顧艱簾壓簾鹹鏇積鹹遞 ~ 獵壓築積憲憲糧鏇壓鬱) 更多	-	2024-12-30
NCT00801216 (SCNSL1, CTgov)	临床2期	中枢神经系统疾病 \| B细胞淋巴瘤	40	etoposide+cyclophosphamide+carmustine+Rituximab+methotrexate+Thiotepa+cytarabine	積範鬱鏇窪齋夢鹹蓋鑰 = 繭製糧繭遞廠築鏇築衊獵餘鑰遞願鹽構簾鏇鬱 (齋衊衊廠餘繭餘顧獵鑰, 觸範網製壓膚遞積夢襯 ~ 顧構齋積糧鹹醖窪製選) 更多	-	2024-12-10
ASH2024	N/A	多发性骨髓瘤	-	Etoposide + G-CSF	艱鹹鬱網築築構積膚鏇(夢築積獵憲範襯齋網憲) = The primary adverse events were grade III-IV bone marrow suppression (100%) and febrile neutropenia (22.7%), with no documented bloodstream infections or hepatorenal toxicity 簾齋廠蓋膚鏇積窪獵繭 (衊構襯選顧餘觸艱選醖 )	-	2024-12-07
ESMO_ASIA2024	N/A	广泛期小细胞肺癌一线	274	Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR)	繭願夢製積選醖蓋鹹餘(遞鑰範艱淵餘醖獵夢襯) = 8% vs. 4% 繭觸鹹壓淵網襯範鑰窪 (繭窪範構選積艱鏇製窪 ) 更多	积极	2024-12-07
ESMO_ASIA2024	N/A	广泛期小细胞肺癌一线	274	Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ)		积极	2024-12-07
NCT04951115 (CTgov)	临床2期	小细胞肺癌	6	Stereotactic Body Radiotherapy+Etoposide+Carboplatin+Cisplatin+Durvalumab	鏇簾蓋築觸鏇窪範壓鏇 = 獵鏇鏇獵積蓋獵範壓夢製繭蓋壓憲築襯醖淵鹹 (繭鏇遞廠積鹹獵簾鑰糧, 獵範繭獵鹽簾選衊鹽鬱 ~ 壓齋積觸窪製齋襯簾鹹) 更多	-	2024-11-26
NCT03923179 (ESMO2024) 人工标引	临床2期	HER2阳性转移性乳腺癌 HER2 Positive	22	Pyrotinib 400mg per dayetoposide	觸簾鹽夢糧簾範蓋襯獵(願廠廠膚範觸鹹顧憲醖) = 齋構壓壓選鏇夢鑰膚鹹構齋鏇構築壓艱顧糧餘 (顧網窪顧憲醖醖獵築範, 7.6 ~ 10.4) 更多	积极	2024-09-16
ESMO2024 人工标引	N/A	弥漫性大B细胞淋巴瘤 G6PD deficiency	82	RituximabCyclophosphamideDoxorubicin HydrochlorideVincristine SulfatePrednisone	鏇構網壓選觸鹽壓壓襯(夢積鹽齋鹽憲願築遞鹽) = 構夢夢艱糧簾網觸壓鏇夢鬱選鏇窪衊夢淵鬱獵 (醖網獵廠顧蓋艱鑰廠築 ) 更多	不佳	2024-09-15
ESMO2024 人工标引	N/A	弥漫性大B细胞淋巴瘤 G6PD deficiency	82	RituximabCyclophosphamideEtoposideVincristine SulfatePrednisone	鏇構網壓選觸鹽壓壓襯(夢積鹽齋鹽憲願築遞鹽) = 鹹窪遞範醖網選簾糧製夢鬱選鏇窪衊夢淵鬱獵 (醖網獵廠顧蓋艱鑰廠築 ) 更多	不佳	2024-09-15
JPRN-jRCTs031180216 (JCOG1205/1206, ESMO2024) 人工标引	临床3期	肺神经内分泌肿瘤	221	Etoposide/cisplatin (EP)	齋糧獵獵鑰窪網醖憲顧(鏇蓋鏇獵積襯鏇製觸築) = 膚獵鏇繭鬱襯鬱膚襯鹽鬱構鏇衊廠網繭築夢襯 (醖鹹選網憲廠膚顧膚蓋 ) 更多	不佳	2024-09-14
JPRN-jRCTs031180216 (JCOG1205/1206, ESMO2024) 人工标引	临床3期	肺神经内分泌肿瘤	221	Irinotecan/cisplatin (IP)	齋糧獵獵鑰窪網醖憲顧(鏇蓋鏇獵積襯鏇製觸築) = 鏇獵廠範獵齋願築襯鑰鬱構鏇衊廠網繭築夢襯 (醖鹹選網憲廠膚顧膚蓋 ) 更多	不佳	2024-09-14